ds3u0slo

Property	Value
?:abstract	Background: We aimed to perform a systematic search and meta-analysis to evaluate the prognostic value of on-admission liver function tests and pre-existing liver diseases on the clinical course of coronavirus disease 2019 (COVID-19). Methods: The study was registered on PROSPERO (CRD42020182902). We searched five databases between 01/01/2020 and 04/23/2020. Studies that reported on liver-related comorbidities and/or laboratory parameters in patients with COVID-19 were included. The main outcomes were COVID-19 severity, intensive care unit (ICU) admission, and in-hospital mortality. Analysis of predictive models hierarchical summary receiver-operating characteristic (HSROC) was conducted with a 95% confidence interval (CI). Results: Fifty studies were included in the meta-analysis. High specificity was reached by acute liver failure associated by COVID-19 (0.94, 95% CI: 0.71–0.99) and platelet count (0.94, 95% CI: 0.71–0.99) in the case of mortality; chronic liver disease (CLD) (0.98, 95% CI: 0.96–0.99) and platelet count (0.82, 95% CI: 0.72–0.89) in the case of ICU requirement; and CLD (0.97, 95% CI: 0.95–0.98), chronic hepatitis B infection (0.97, 95% CI: 0.95–0.98), platelet count (0.86, 95% CI: 0.77–0.91), and alanine aminotransferase (ALT) (0.80, 95% CI: 0.66–0.89) and aspartate aminotransferase (AST) (0.84, 95% CI: 0.77–0.88) activities considering severe COVID-19. High sensitivity was found in the case of C-reactive protein (CRP) for ICU requirement (0.92, 95% CI: 0.80–0.97) and severe COVID-19 (0.91, 95% CI: 0.82–0.96). Conclusion: On-admission platelet count, ALT and AST activities, CRP concentration, and the presence of acute and CLDs predicted the severe course of COVID-19. To highlight, pre-existing liver diseases or acute liver injury associated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection plays an important role in the prediction of mortality.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/ds3u0slo_hasAnnotation_C0055926> <https://research.tib.eu/covid-19/entity/ds3u0slo_hasAnnotation_C0242656> <https://research.tib.eu/covid-19/entity/ds3u0slo_hasAnnotation_C1266129> <https://research.tib.eu/covid-19/entity/ds3u0slo_hasAnnotation_C1415181> <https://research.tib.eu/covid-19/entity/ds3u0slo_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/V%C3%A1ncsa%2C_Szil%C3%A1rd%3B_Hegyi%2C_P%C3%A9ter_Jeno%3B_Z%C3%A1dori%2C_No%C3%A9mi%3B_Szak%C3%B3%2C_Lajos%3B_V%C3%B6rhendi%2C_N%C3%B3ra%3B_Ocskay%2C_Klementina%3B_F%C3%B6ldi%2C_M%C3%A1ria%3B_Dembrovszky%2C_Fanni%3B_D%C3%B6m%C3%B6t%C3%B6r%2C_Zsuzsa_R%C3%A9ka%3B_J%C3%A1nosi%2C_Krist%C3%B3f%3B_Rakonczay%2C_Zolt%C3%A1n%3B_Hartmann%2C_Petra%3B_Horv%C3%A1th%2C_Tamara%3B_Er%C5%91ss%2C_B%C3%A1lint%3B_Kiss%2C_Szabolcs%3B_Szak%C3%A1cs%2C_Zsolt%3B_N%C3%A9meth%2C_D%C3%A1vid%3B_Hegyi%2C_P%C3%A9ter%3B_P%C3%A1r%2C_Gabriella>
?:doi	<https://research.tib.eu/covid-19/entity/10.3389/fmed.2020.572115>
?:doi	10.3389/fmed.2020.572115
?:journal	Front_Med_(Lausanne)
?:license	cc-by
?:pdf_json_files	document_parses/pdf_json/f2255925c49dc22f8b025dc0dda58d684e5a6bd7.json
?:pmc_json_files	document_parses/pmc_json/PMC7691431.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7691431>
?:pmid	<https://research.tib.eu/covid-19/entity/33282888.0>
?:pmid	33282888.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/f2255925c49dc22f8b025dc0dda58d684e5a6bd7>
?:source	Medline; PMC
?:title	Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-13

Property

Value

?:abstract

Background: We aimed to perform a systematic search and meta-analysis to evaluate the prognostic value of on-admission liver function tests and pre-existing liver diseases on the clinical course of coronavirus disease 2019 (COVID-19). Methods: The study was registered on PROSPERO (CRD42020182902). We searched five databases between 01/01/2020 and 04/23/2020. Studies that reported on liver-related comorbidities and/or laboratory parameters in patients with COVID-19 were included. The main outcomes were COVID-19 severity, intensive care unit (ICU) admission, and in-hospital mortality. Analysis of predictive models hierarchical summary receiver-operating characteristic (HSROC) was conducted with a 95% confidence interval (CI). Results: Fifty studies were included in the meta-analysis. High specificity was reached by acute liver failure associated by COVID-19 (0.94, 95% CI: 0.71–0.99) and platelet count (0.94, 95% CI: 0.71–0.99) in the case of mortality; chronic liver disease (CLD) (0.98, 95% CI: 0.96–0.99) and platelet count (0.82, 95% CI: 0.72–0.89) in the case of ICU requirement; and CLD (0.97, 95% CI: 0.95–0.98), chronic hepatitis B infection (0.97, 95% CI: 0.95–0.98), platelet count (0.86, 95% CI: 0.77–0.91), and alanine aminotransferase (ALT) (0.80, 95% CI: 0.66–0.89) and aspartate aminotransferase (AST) (0.84, 95% CI: 0.77–0.88) activities considering severe COVID-19. High sensitivity was found in the case of C-reactive protein (CRP) for ICU requirement (0.92, 95% CI: 0.80–0.97) and severe COVID-19 (0.91, 95% CI: 0.82–0.96). Conclusion: On-admission platelet count, ALT and AST activities, CRP concentration, and the presence of acute and CLDs predicted the severe course of COVID-19. To highlight, pre-existing liver diseases or acute liver injury associated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection plays an important role in the prediction of mortality.

is ?:annotates of